Luckprom, P <br/><br/>
Adenosine triphosphate stimulates RANKL expression through P2Y1 receptor-cyclo-oxygenase-dependent pathway in human periodontal ligament cells.  [electronic resource] 

 -  Journal of periodontal research  Jun 2010 
 - 404-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0765 
<br/><br/><label>Standard No.: </label>10.1111/j.1600-0765.2009.01256.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenosine Diphosphate--analogs & derivatives<br/>Adenosine Triphosphate--pharmacology<br/>Biomechanical Phenomena<br/>Bone Remodeling--physiology<br/>Bone Resorption--physiopathology<br/>Cells, Cultured<br/>Cyclic AMP-Dependent Protein Kinases--antagonists & inhibitors<br/>Cyclooxygenase 2--drug effects<br/>Cyclooxygenase 2 Inhibitors--pharmacology<br/>Dinoprostone--antagonists & inhibitors<br/>Enzyme Inhibitors--pharmacology<br/>Estrenes--pharmacology<br/>Humans<br/>Indomethacin--pharmacology<br/>Isoquinolines--pharmacology<br/>NF-kappa B--antagonists & inhibitors<br/>Periodontal Ligament--cytology<br/>Phosphodiesterase Inhibitors--pharmacology<br/>Purinergic P2 Receptor Antagonists<br/>Pyrrolidines--pharmacology<br/>Pyrrolidinones--pharmacology<br/>RANK Ligand--antagonists & inhibitors<br/>RNA, Small Interfering--pharmacology<br/>Receptors, Purinergic P2--drug effects<br/>Receptors, Purinergic P2Y1<br/>Sulfonamides--pharmacology<br/>Thiocarbamates--pharmacology<br/>Type C Phospholipases--antagonists & inhibitors